The guidelines from the New York State Workers Compensation Board provide general principles for Adrenergic Inhibitors. These directives aim to assist healthcare professionals in determining appropriate strategies for utilizing medications that inhibit adrenergic activity, forming part of a comprehensive treatment plan.
Healthcare practitioners specializing in Adrenergic Inhibitors can rely on the guidance from the Workers Compensation Board to make well-informed decisions about the most suitable approaches for employing these medications in the care of their patients.
It is crucial to emphasize that these guidelines are not intended to replace clinical judgment or professional expertise. The ultimate decision regarding the use of Adrenergic Inhibitors should involve collaboration between the patient and their healthcare provider.
Adrenergic Inhibitors
Propranolol isn’t advised for treating patients with PTSD, and there’s evidence against its use.
Prazosin is not recommended for the overall treatment of global PTSD symptoms. However, it is recommended for select patients with PTSD who experience prominent nightmares and/or sleep disturbances. Discontinuation should be considered if there’s a lack of efficacy, adverse effects, non-compliance, or if the resolution of PTSD reaches a point where medication isn’t needed anymore.
Guanfacine is not recommended for treating patients with PTSD, and there’s evidence against its use.
Similarly, Clonidine is not recommended for the treatment of patients with PTSD.
Doxazosin is not recommended for treating patients with PTSD, and there’s evidence against its use.
